Figure 6.
RESPOND study design. Distribution and outcome of corresponding DrotAA (Xigris®)-treated PROWESS [9] patients. DrotAA, drotrecogin alfa (activated); EOI, end of
infusion; LLN, lower limit of normal; PC, protein C; PROWESS, Recombinant Human Activated
Protein C Worldwide Evaluation in Severe Sepsis; RESPOND, Research Evaluating Serial
Protein C levels in severe sepsis patients ON Drotrecogin alfa [activated]. †Mortality.
Vangerow et al. Critical Care 2007 11(Suppl 5):S4 doi:10.1186/cc6155 |
